IDH1 and acute myeloid leukemia: Among the inhibitors of the IDH1 mutated isoform currently used in clinical settings, there is ivosidenib (AG-120), which was FDA-approved in 2018 for the treatment of relapsed or refractory AML with a susceptible IDH1 mutation.